Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heterogeneity of the MYCN Oncogene in Neuroblastoma

11 Mar 2009

Abstract excerpt

PURPOSE: MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity. EXPERIMENTAL DESIGN: The MYCN status was investigated by fluorescence in situ hybridization at diagnosis and relapse. Heterogeneity was defined as the simultaneous presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19276282
DOI: 10.1158/1078-0432.ccr-08-1648

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heterogeneity of the MYCN Oncogene in NeuroblastomaPMID 19276282Read ↗

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudySemantic proximity Read ↗

Heterogeneity of <i>MYCN</i> amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasisSemantic proximity Read ↗

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Tumoral heterogeneity in neuroblastomaSemantic proximity Read ↗

Molecular basis for heterogeneity in human neuroblastomasSemantic proximity Read ↗

Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectSemantic proximity Read ↗

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratificationSemantic proximity Read ↗

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.Semantic proximity Read ↗

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group studySemantic proximity Read ↗

The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.Semantic proximity Read ↗

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.